Tofacitinib in the Treatment of IgG4 Related Diseases

Summary

This study is a single centre, open label, randomized controlled study to compare the efficacy and safety between steroids plus tofacitinib and steroids alone in active IgG4-related diseases patients. It is expected to enroll a total of 58 IgG4 RD patients. The sample size of two groups is 1:1. The primary end points of this study is to compare the IgG4-RD response rate between two groups at 24 weeks.

Timeline

Start

2023-04-01

Primary completion

2026-06-03

Completion

2026-06-03

Drugs

Indications